+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Revenue Cycle Management for Oncology And Urology Market Size, Share & Trends Analysis Report By Sourcing (In-house, External RCM Apps/ Software, Outsourced RCM Services), By End Use, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 68 Pages
  • November 2022
  • Region: United States
  • Grand View Research
  • ID: 5702169
The U.S. revenue cycle management for oncology and urology market is expected to reach USD 22.3 billion by 2030. The market is expected to expand at a CAGR of 13.7% from 2023 to 2030. The market growth can be attributed to the rising adoption of applications that would help in streamlining revenue cycles for various healthcare institutions and technological advancements undertaken by the key players in the market.

Developers and vendors of RCM platforms & solutions are supporting healthcare facilities in accommodating and getting themselves accustomed to the transitions associated with ICD-10. RCM providers are focusing on increasing staff resources & providing adequate training sources and improving customer engagement. For instance, in January 2020, OnQ launched Robotic Process Automation (RPA). The company’s accessible RPA solutions considerably helped in enhancing service quality, improving efficiencies, and shortening medical billing procedures.

According to The State of RPA in the Revenue Cycle survey conducted in 2021, 51% of the healthcare systems in the U.S. are widely adopting Robotic Process Automation (RPA) in improving their RCM platforms. RPA and automation allow to streamline and simplify various aspects of the RCM solution that is repetitive, manual, or rule-based. The survey further states that midsized and large-sized hospitals are using automation across all functions of their RCM platform. The top five RCM processes wherein automation is widely being used are Eligibility (59%), Authorization (57%), Claims/Follow-up (43%), Charge Capture (39%), and Payments/Collections (39%).

Increasing adoption of RCM outsourcing in the U.S. is expected to positively impact the growth of the market during the forecast period. The changing aspects of RCM outsourcing are mainly due to the availability of finances, value addition, and business prospects. Moreover, due to awareness regarding cost savings with respect to the adoption of RCM solutions, efficient and cost-effective services are some of the major advantages of RCM outsourcing. Despite this, the shortage of skilled professionals required for managing the revenue cycle management software is expected to restrain the growth of the market over the forecast period.

U.S. Revenue Cycle Management For Oncology And Urology Market Report Highlights

  • In 2022, in house segment held the largest share of 72.9%. Higher adoption of in-house RCM software due to flexibility in the functioning of the software is one of the significant factors contributing to segmental growth.
  • In 2022, the hospital segment held the largest share of 58.6% due to the rising adoption of RCM solutions to manage the financial aspects of the hospitals.
  • The key players in the market have been involved in mergers and acquisitions to increase their share in the market and provide innovative solutions to the end-users which is anticipated to boost the market growth during the forecast period.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.2 Research Process
1.2.1 Information Procurement
1.2.1.1 Purchased Database
1.2.1.2 Internal Database
1.2.2 Primary Research
1.3 Research Methodology for Parent Market (U.S. RCM Market)
1.3.1 Company Market Share
1.3.2 Market Estimations
1.3.2.1 RCM Market Estimation
1.3.2.2 RCM Outsourcing Market Estimation
1.3.2.3 In-House U.S. RCM Market Estimation
1.3.2.4 U.S. RCM Market Estimation
1.3.2.5 Oncology And Urology Practices in the U.S. estimation
1.3.3 Country Market: CAGR Calculation
1.4 Country-based Segment Share Calculation
1.4.1 Segmental Market Estimation for Oncology and Urology:
1.5 List of Data Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 U.S. Revenue Cycle Management for Oncology and Urology Market Variables, Trends & Scope
3.1 U.S. Revenue Cycle Management for Oncology and Urology Market Snapshot
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Technological Advancements
3.3.1.2 Increase in outsourcing of RCM
3.3.1.3 Increasing adoption of mHealth
3.3.1.4 Growth of High-Deductible Health Plans (Hdhps)
3.3.2 Market Restraint Analysis
3.3.2.1 Increasing Payer Partnerships
3.3.2.2 Lack Of Professionals To Handle RCM Processes
3.4 U.S. Revenue Cycle Management Market Analysis Tools
3.4.1 Industry Analysis - Porter’s Five Forces
3.4.1.1 Bargaining Power Of Suppliers-Moderate
3.4.1.2 Bargaining Power Of Buyers- Moderate
3.4.1.3 Threat Of Substitution- Low
3.4.1.4 Threat Of New Entrants- Moderate
3.4.1.5 Competitive Rivalry- High
3.5 Number of Oncology and Urology Practices in the U.S.
3.5.1 Estimated total number of oncology hospitals & practices, 2021
3.5.2 Estimated total number of oncology hospitals & practices, 2021, By Size
3.5.3 Estimated total number of urology hospitals & practices, 2021
3.6 Penetration Rates of In-house vs Outsourced RCM Services for Oncology
3.6.1 Community Practices
3.6.2 Hospitals
3.7 Penetration Rates of In-house vs Outsourced RCM Services for Urology
3.7.1 Community Practices
3.7.2 Hospitals
3.8 Contract Agreement Framework
3.8.1 Hospitals
3.8.1.1 Medium-Sized Hospitals
3.8.1.2 Large-Sized Hospitals
3.9 Impact of COVID-19 Pandemic on the U.S. Revenue Cycle Management for Oncology and Urology Market
Chapter 4 U.S. Revenue Cycle Management for Oncology and Urology Market: Sourcing Market Estimates & Trend Analysis
4.1 U.S. Revenue Cycle Management for Oncology and Urology Market: Sourcing Analysis
4.1.1 In-House
4.1.1.1 In-House market value estimates and forecasts, 2016 - 2030 (USD Billion)
4.1.2 External RCM Apps/ Software
4.1.2.1 External RCM Apps/ Software market value estimates and forecasts, 2016 - 2030 (USD Billion)
4.1.3 Outsourced RCM Services
4.1.3.1 Outsourced RCM Services market value estimates and forecasts, 2016 - 2030 (USD Billion)
Chapter 5 U.S. Revenue Cycle Management for Oncology and Urology Market: End-Use Market Estimates & Trend Analysis
5.1 U.S. Revenue Cycle Management for Oncology and Urology Market: End-Use Analysis
5.1.1 Physicians and Clinical Services
5. Physicians and clinical services market value estimates and forecasts, 2016 - 2030 (USD Billion)
5.1.2 Hospitals
5.1.2.1 Hospitals market value estimates and forecasts, 2016 - 2030 (USD Billion)
Chapter 6 U.S. Revenue Cycle Management for Oncology and Urology Market: Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Company Market Position Analysis
6.3 List of Key Competitors in Urology and Oncology with their Key Clientele
Chapter 7 Competitive Landscape
7.1 Company Profiles
7.1.1 United Urology Group
7.1.1.1 Company Overview
7.1.1.2 Financial Performance
7.1.1.3 Product Benchmarking
7.1.1.4 Strategic Initiatives
7.1.2 Cardinal Health
7.1.2.1 Company Overview
7.1.2.2 Financial Performance
7.1.2.3 Product Benchmarking
7.1.3 Flatiron
7.1.3.1 Company Overview
7.1.3.2 Financial Performance
7.1.3.3 Product Benchmarking
7.1.3.4 Strategic Initiatives
7.1.4 Oncospark.com
7.1.4.1 Company Overview
7.1.4.2 Financial Performance
7.1.4.3 Product Benchmarking
7.1.4.4 Strategic Initiatives
7.1.5 Fedora Solutions
7.1.5.1 Company Overview
7.1.5.2 Financial Performance
7.1.5.3 Product Benchmarking
7.1.6 BillingParadise
7.1.6.1 Company Overview
7.1.6.2 Financial Performance
7.1.6.3 Product Benchmarking
7.1.7 Gentem
7.1.7.1 Company Overview
7.1.7.2 Financial Performance
7.1.7.3 Product Benchmarking
7.1.7.4 Strategic Initiatives
7.1.8 Integra Connect, LLC
7.1.8.1 Company Overview
7.1.8.2 Financial Performance
7.1.8.3 Product Benchmarking
7.1.8.4 Strategic Initiatives
7.1.9 R1 RCM, Inc.
7.1.9.1 Company Overview
7.1.9.2 Financial Performance
7.1.9.3 Product Benchmarking
7.1.9.4 Strategic Initiatives
List of Tables
Table 1 Estimated total number of oncology hospitals and practices, 2021
Table 2 Estimated total number of oncology hospitals and practices, by size, 2021
Table 3 Estimated total number of urology hospitals and practices
Table 4 Penetration rate of in-house vs outsourced RCM services for oncology in community practices (%)
Table 5 Penetration rate of in-house vs outsourced RCM services for oncology in hospitals (%)
Table 6 Penetration rate of in-house vs outsourced RCM services for urology in community practices (%)
Table 7 Penetration rate of in-house vs outsourced RCM services for urology in hospitals (%)
Table 8 Contract agreement framework in medium-sized hospitals
Table 9 Contract agreement framework in large-sized hospitals
List of Figures
Fig. 1 U.S. revenue cycle management for oncology and urology market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Research methodology: U.S. RCM market
Fig. 6 U.S. revenue cycle management for oncology and urology market trends & outlook
Fig. 7 Penetration & growth prospect mapping
Fig. 8 Market driver analysis (Current & future impact)
Fig. 9 Market restraint analysis (Current & future impact)
Fig. 10 U.S. revenue cycle management for oncology and urology market, sourcing outlook: Key takeaways (USD Billion)
Fig. 11 U.S. revenue cycle management for oncology and urology market: Sourcing movement analysis (USD Billion)
Fig. 12 In-house market estimates and forecasts, 2016 - 2030 (USD Billion)
Fig. 13 External RCM apps/software market estimates and forecasts, 2016 - 2030 (USD Billion)
Fig. 14 Outsourced RCM services market estimates and forecasts, 2016 - 2030 (USD Billion)
Fig. 15 U.S. revenue cycle management for oncology and urology market, end-use outlook: Key takeaways (USD Billion)
Fig. 16 U.S. revenue cycle management for oncology and urology market: End-use movement analysis (USD Billion)
Fig. 17 Physicians and clinical services market estimates and forecasts, 2016 - 2030 (USD Billion)
Fig. 18 Hospitals market estimates and forecasts, 2016 - 2030 (USD Billion)
Fig. 19 Company market position analysis, 2022
Fig. 20 Estimated share of in-house vs outsourced RCM solutions in oncology

Companies Mentioned

  • United Urology Group
  • Cardinal Health
  • Flatiron
  • Oncospark.Com
  • Fedora Solutions
  • Billingparadise
  • Gentem
  • Integra Connect, LLC
  • R1 Rcm, Inc.

Methodology

Loading
LOADING...